HIM
ANAB icon

Hillsdale Investment Management’s AnaptysBio ANAB Stock Holding History

Hillsdale Investment Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Buy
5,150
+530
+11% +$32.1K 0.01% 505
2026
Q1 		$256K Buy
+4,620
New +$249K 0.01% 542
2018
Q2 		– Sell
-900
Closed -$94K – 493
2018
Q1 		$94K Buy
+900
New +$101K 0.01% 289

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Hillsdale Investment Management's ANAB Position: Q2 2026 in Review

Hillsdale Investment Management increased its AnaptysBio (ANAB) stake by 11% in Q2 2026, buying an estimated $32.1K and bringing the position to 5,150 shares worth $348K. The position accounts for 0.01% of the portfolio, ranked #505.

Hillsdale Investment Management first reported a position in ANAB in Q1 2018 and has held it in 3 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Hillsdale Investment Management held 5,150 shares of AnaptysBio worth $348K as of Q2 2026.
  • Hillsdale Investment Management bought 530 AnaptysBio shares in Q2 2026, an estimated $32.1K.
  • AnaptysBio made up 0.01% of Hillsdale Investment Management's portfolio in Q2 2026, its #505 holding.
  • Hillsdale Investment Management first reported a position in AnaptysBio in Q1 2018 and has held it in 3 quarters since.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.